MRI引导下空心针活检检出的高危病变:手术切除后的升级率及其对管理的意义
该研究回顾性分析了2015年1月1日至2018年11月30日在一家学术性乳腺放射学中心接受MRI引导下空心针活检的女性,评估高危病变的升级率及预测恶性的临床和影像特征。159例高危病变中13例(8.2%)升级为癌,ADH升级率为22.5%(9/40),FEA为33.3%(1/3),LCIS为6.3%(3/48),ALH、放射状瘢痕、乳头状瘤和良性血管病变均为0.0%。结论认为MRI引导下空心针活检诊断的ADH需手术切除,其他高危病变在精细影像-病理对照后可能适合影像随访而非切除。
要点
- MRI引导下空心针活检诊断的ADH手术升级率达22.5%(9/40),显著高于非ADH病变(p=.005)。
- FEA升级率为33.3%(1/3),LCIS为6.3%(3/48),ALH、放射状瘢痕、乳头状瘤和良性血管病变均为0.0%。
- 69.2%(9/13)的升级病变为导管原位癌或高分化癌。
核心结论
- MRI引导下空心针活检诊断的ADH需手术切除。
- 其他高危病变在精细影像-病理对照后可能适合影像随访而非切除。
研究设计与样本
- 回顾性研究,纳入2015年1月1日至2018年11月30日在一家学术性乳腺放射学中心接受MRI引导下空心针活检的所有女性。
- 810例MRI引导下活检中189例(23.3%)符合高危病变纳入标准,排除30例后最终研究队列为159例高危病变。
- 排除原因:15例失访,6例活检后接受新辅助化疗,2例未切除且影像随访不足2年,7例回顾性阅片存在影像-病理不一致。
- 记录临床病史、影像特征、手术结局和随访数据,并进行影像-病理对照。
诊断标准与关键数值
- 159例高危病变中13例(8.2%)升级为癌。
- ADH升级率22.5%(9/40),FEA升级率33.3%(1/3),LCIS升级率6.3%(3/48)。
- ALH升级率0.0%(0/11),放射状瘢痕0.0%(0/28),乳头状瘤0.0%(0/26),良性血管病变0.0%(0/3)。
- ADH病变升级可能性显著高于非ADH病变(p=.005)。
- 升级病变中69.2%(9/13)为导管原位癌或高分化癌。
临床应用与阅片要点
- MRI引导下空心针活检诊断的ADH需手术切除。
- 其他高危病变(LCIS、ALH、放射状瘢痕、乳头状瘤、FEA、良性血管病变、黏液囊肿样病变)在精细影像-病理对照后可能适合影像随访而非切除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of our study was to evaluate the upgrade rates of high-risk lesions (HRLs) diagnosed by MRI-guided core biopsy and to assess which clinical and imaging characteristics are predictive of upgrade to malignancy. MATERIALS AND METHODS. A retrospective review was performed of all women who presented to an academic breast radiology center for MRI-guided biopsy between January 1, 2015, and November 30, 2018. Histopathologic results from each biopsy were extracted. HRLs-that is, atypical ductal hyperplasia (ADH), lobular carcinoma in situ (LCIS), atypical lobular hyperplasia (ALH), radial scar, papilloma, flat epithelial atypia (FEA), benign vascular lesion (BVL), and mucocelelike lesion-were included for analysis. Clinical history, imaging characteristics, surgical outcome, and follow-up data were recorded. Radiologic-pathologic correlation was performed. RESULTS. Of 810 MRI-guided biopsies, 189 cases (23.3%) met the inclusion criteria for HRLs. Of the 189 HRLs, 30 cases were excluded for the following reasons: 15 cases were lost to follow-up, six cases were in patients who received neoadjuvant chemotherapy after biopsy, two lesions that were not excised had less than 2 years of imaging follow-up, and seven lesions had radiologic-pathologic discordance at retrospective review. Of the 159 HRLs in our study cohort, 13 (8.2%) were upgraded to carcinoma. Surgical upgrade rates were high for ADH (22.5%, 9/40) and FEA (33.3%, 1/3); moderate for LCIS (6.3%, 3/48); and low for ALH (0.0%, 0/11), radial scar (0.0%, 0/28), papilloma (0.0%, 0/26), and BVL (0.0%, 0/3). Of the upgraded lesions, 69.2% (9/13) were upgraded to ductal carcinoma in situ (DCIS) or well-differentiated carcinoma. ADH lesions were significantly more likely to be upgraded than non-ADH lesions (p = .005). CONCLUSION. ADH diagnosed by MRI-guided core biopsy warrants surgical excision. The other HRLs, however, may be candidates for imaging follow-up rather than excision, especially after meticulous radiologic-pathologic correlation.
引用
- Michaels AY, Ginter PS, Dodelzon K, et al. High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management. AJR Am J Roentgenol. 2021. PMID: 33439046. doi:10.2214/AJR.20.23040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。